AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02711358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indomethacin suppositories
Description: The patients will be instructed to self-administer a single rectal dose of 50 mg indomethacin 30 min before the scheduled time of the procedure
Study NCT02711358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The patient swill be instructed to self-administer a single rectal dose of placebo 30 min before the scheduled time of the procedure
Study NCT02837393 — intervention group
Intervention type: PROCEDURE
Intervention: Ureteral catheterization
Description: During ureteral catheterization, urine samples will be obtain from each kidney
Study NCT01624285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO
Study NCT01624285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01624285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01624285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02890355 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02890355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT02890355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT02890355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT03881605 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI screening
Description: A standard contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain will be performed at baseline, 4 months, 8 months and 12 months.
Study NCT02194894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: acetaminophen will be given for patient for both arms for 14 days
Study NCT03945071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Punctal plug
Description: Punctal plug will be given to subjects after intravitreal injection in half of the study subjects
Study NCT01635621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab (OKZ)
Description: Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period:~* OKZ 120 mg every 2 weeks~* OKZ 240 mg every 2 weeks~* OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0~1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0.
Study NCT01635621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.
Study NCT02182986 — intervention group
Intervention type: PROCEDURE
Intervention: transplant
Description: All subjects enrolled in this study are candidates for/recipients of solid organ transplants as a therapeutic for end stage diseases (e.g., heart, liver, heart with liver, kidney, small intestine, or liver with small intestine transplants).
Study NCT02182986 — intervention group
Intervention type: DRUG
Intervention: Immunosuppressive Drugs
Description: Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.
Study NCT00738426 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia ML Scanner (MLS)
Description: Red diode low level laser light energy.
Study NCT00738426 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: non-therapeutic light energy output
Study NCT01213446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate
Description: PK component: Single bolus infusion of 80 IU VWF:RCo/kg administered intravenously on Day 1, and approximately Day 180 in Type 3 VWD subjects only.~Efficacy component: Repeated bolus doses over 12 months as required to manage VWD condition.
Study NCT03339713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF
Description: Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp.
Study NCT03339713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: Fluarix will be administered as intramuscular injection.
Study NCT03339713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as intramuscular injection of sterile 0.9 percent (%) saline for injection.
Study NCT01395810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.
Study NCT01395810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: One single dose administered intravenously (into the vein). Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode.
Study NCT01395810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: One single dose administered intravenously (into the vein) every second week. Patients will receive instruction on how to treat any bleeding episode they may experience.
Study NCT00490919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system
Description: Buprenorphine transdermal system 10 or 20 mcg/h worn for 7 days
Study NCT00490919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: transdermal system (placebo) worn for 7 days
Study NCT03770026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: Clomiphene citrate-only arm: Patients will receive Clomiphene citrate induction (in a dose of 100 mg/day starting from day 3 of the cycle for 5 days). Sonographic assessment of endometrial thickness together with Power Doppler evaluation endometrial and sub-endometrial blood flow a will be done in the Day of HCG injection.
Study NCT03770026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Description: Clomiphene citrate-only arm: Patients will receive Clomiphene citrate induction (in a dose of 100 mg/day starting from day 3 of the cycle for 5 days). Sonographic assessment of endometrial thickness together with Power Doppler evaluation endometrial and sub-endometrial blood flow a will be done in the Day of HCG injection.
Study NCT03770026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline cervical flushing
Description: Cervical irrigation with 1 ml of 0.9% normal saline will be done at cycle day 8 and 10 to convince patient-blinded procedure.
Study NCT03770026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrauterine Autologous platelet-rich plasma
Description: Under complete aseptic cares and ultrasound supervision, Autologous platelet-rich plasma (0.5 - 1 ml) was immediately injected into the uterine cavity using an intrauterine insemination catheter in the cycle days 8 and 10. The Autologous platelet-rich plasma is prepared in collaboration with the Department of Clinical Pathology, Faculty of Medicine, Benha University.
Study NCT04265261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive oral placebo matched to RG7774
Study NCT04265261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7774
Description: Participants will receive oral RG7774
Study NCT02660684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: Injection or oral
Study NCT02660684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Injection
Study NCT02660684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Injection
Study NCT02660684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Injection or oral
Study NCT01865656 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skills training
Description: Refresher training on Basic Emergency Obstetric and Newborn care
Study NCT01865656 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emergency obstetric drills
Description: Emergency obstetric drills to practice timely and appropriate management of postpartum hemorrhage and preeclampsia/eclampsia
Study NCT01865656 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Revised Case Sheets
Description: Revised case sheets will be introduced to capture the timing and appropriate medical treatment of women in labor and newborns
Study NCT01865656 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supportive supervision
Description: Quarterly supportive supervision visits each of the intervention first referral units.
Study NCT01865656 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Referral strengthening
Description: To support referral systems that ensure timely and appropriate treatment for obstetric emergencies
Study NCT01863615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin 40 mg
Description: Roaccutan 2 capsules of 20 mg; reference drug
Study NCT01863615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin 40 mg
Description: Oratane 2 capsules of 20 mg; test drug
Study NCT03074461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Side-to-End Anastomosis
Description: During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a side-to-end colorectal anastomosis.
Study NCT03074461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse Coloplasty
Description: During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a transverse coloplasty pouch. For this purpose an end-to-end colorectal anastomosis is initially performed, followed by a longitudinal incision of approx. 8-10 cm length proximal of the anastomosis and a subsequent transverse suture in terms of the coloplasty technique.
Study NCT04316260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation e-visit
Description: electronic visits (e-visits) for smoking cessation
Study NCT04316260 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
Study NCT03271632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T cells
Description: Infusion of multi-CAR T cells
Study NCT00826410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Redon drain
Description: subcutaneous suction drain after laparotomy for two days
Study NCT02232477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal recombinant human alpha iduronidase
Description: Intrathecal recombinant human alpha iduronidase every 3 months
Study NCT01932749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic stimulation
Study NCT02000622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
Study NCT02000622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's choice chemotherapy
Description: Investigators will declare one of the following regimens:~* Capecitabine 2500 mg/m2 po daily (divided in 2 doses) x 14 days, repeat every 21 days~* Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days
Study NCT04271202 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Emgality 120 MG in 1 ML Prefilled Syringe
Description: Initial dose of 240 mg followed by 2 interventions (1 month apart) of 120 mg - all given as injectables.
Study NCT04482907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Giving dill by mouth capsule to the study group and placebo capsule by mouth to the control group.
Description: Tests from intravenous blood: TSH, fT3, fT4, anti-TPO, Anti-Tg, CRP
Study NCT04482907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Giving dill by mouth capsule to the study group and placebo capsule by mouth to the control group.
Description: Tests from intravenous blood: TSH, fT3, fT4, anti-TPO, Anti-Tg, CRP
Study NCT01330550 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fiber sugar free biscuit
Description: Dosage form:Biscuit, Dosage:1.94gram fiber/slice, Frequency:9 slices/meal;3 times/day. Duration:8 weeks
Study NCT01221558 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lycopene
Study NCT01221558 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lycopene
Study NCT00497146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: 2 µg capsule
Study NCT00497146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule
Study NCT02634619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventral buccal mucosa onlay urethroplasty
Description: Ventral buccal graft onlay involves a midline perineal incision and retraction of the bulbospongiosum muscle downward to expose the ventral urethral surface. The corpus spongiosum is incised longitudinally to expose the urethral lumen and the incision is extended proximal and distal to the established stricture. The buccal mucosa graft is harvested and trimmed to the length and width of the urethrotomy and the graft is sutured at the proximal and distal apices and a running suture at the lateral margins to establish a tight anastomosis. Ventral placement allows for limited urethral mobilization and easy access, but there is concern about higher likelihood of diverticulum formation and development of other associated complications - such as post void dribbling and ejaculatory dysfunction.
Study NCT02634619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal buccal mucosa onlay urethroplasty
Description: Dorsal buccal onlay also involves a midline perineal incision. The bulbo-cavernosum and corpora cavernosum are dissected from the bulbar urethra allowing for complete mobilization of the urethra. The urethra is rotated 180 degrees to allow for dorsal access and an incision is made on the dorsal urethra proximal and distal to the stricture location. The buccal graft is harvested and trimmed to the appropriate size of the urethrotomy and spread on the overlying tunica albuginea of the corporal bodies. The urethra is rotated back to allow for suturing of the left mucosal margin to the left margin of the buccal graft and corporal bodies, essentially covering the entire urethral plate. Dorsal placement has potential for a more stable vascular bed for graft sustainability and less spongiosal bleeding, but requires a greater urethral mobilization and longer operative times.
Study NCT02413671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Lupin Protein
Description: Subjects received a standardized test meal rich in carbohydrates and supplemented with lupin protein.
Study NCT02413671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey Protein
Description: Subjects received a standardized test meal rich in carbohydrates and supplemented with whey protein.
Study NCT02413671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reference
Description: Subjects received a standardized test meal rich in carbohydrates and not supplemented with any protein.
Study NCT03628833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incontinence Management System
Description: Incontinence detection device
Study NCT04418141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN1
Description: Participants will receive CN1 by IV infusion on Day 1 of each cycle (every 3 weeks). The 5 planned dose levels are 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg.
Study NCT03336541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine (0.5 mg/kg in 100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
Study NCT03336541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
Study NCT03714100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance
Description: Participants will attend one-hour Tai Ji Quan: Moving for Better Balance classes twice a week for 16-weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
Study NCT03287700 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be administered to any group in this observational study.
Study NCT03982966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids (fish oil) 1000 mg/day oral
Description: Omega 3 fatty acids (fish oil) 1000 mg/day oral
Study NCT02204644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumatinib 600mg qd
Study NCT02204644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib 400mg qd
Study NCT03272347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.
Study NCT03272347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Islatravir
Description: Placebo to islatravir is orally administered QD in capsule form for up to 52 weeks
Study NCT03272347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks
Study NCT03272347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Doravirine
Description: Placebo to Doravirine is orally administered QD in tablet form for up to 52 weeks
Study NCT03272347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks
Study NCT03272347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Lamivudine
Description: Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks
Study NCT03272347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Description: Fixed dose combination of 100 mg doravirine + 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 144 weeks.
Study NCT03272347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Description: Placebo to doravirine/lamivudine/tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 52 weeks
Study NCT03272347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doravirine/Islatravir
Description: Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks
Study NCT03272347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine/Islatravir
Description: Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks
Study NCT02349139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN001: Escalating dose Part A
Description: Androgen inhibitor
Study NCT02562599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltitrexed-cisplatin
Description: Patients receive raltitrexed-cisplatin neoadjuvant chemotherapy every three weeks for two cycles, then receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
Study NCT02562599 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Description: Patients receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
Study NCT01085422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888
Description: Subjects will be given ABT-888 on Days 1 -7 every 28 days orally and temozolomide on days 1-5 on days 1-5 every 28 days orally with ABT-888
Study NCT01085422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Subjects will be given ABT-888 40 mg twice daily on Days 1 -7 every 28 days orally and temozolomide on days 1-5 every 28 days orally with ABT-888